StockMarketTrends
-
The Fed’s Pause Is a Litmus Test — Stop Trading Like Cuts Are Guaranteed
The Fed just hit pause — and traders are already picking sides. At its late-January meeting, the Federal Reserve held rates at 3.50%–3.75% after three cuts in late 2025. Officials are signaling two more cuts later this year, but Dallas Fed President Lorie Logan threw cold water on any “cut now” enthusiasm, warning against moving…
-
Nebius Is Priced Like a Winner — But It Hasn’t Won Yet
$88 a share. Nearly $25B market cap. And still losing money. NBIS — Nebius Group — is the latest AI infrastructure darling that investors can’t seem to quit. On paper, it looks like a rocket ship: revenue up more than 300% year over year, headline-grabbing multibillion-dollar contracts with Microsoft and Meta, and a narrative that…
-
Hims Isn’t a Compounder Right Now — It’s a Trade With a Lab Coat
Hims stock looks like a healthcare compounder at first glance. Sticky subscriptions. Fat gross margins. A brand people actually recognize. But right now? This thing is trading more like a momentum bet wrapped in a lab coat. Here’s the bull case, and it’s real. Hims didn’t luck its way into growth. Revenue jumped nearly 70%…
-
NVIDIA Is a Great Company — and a Dangerous Trade
You must be logged in to post a comment.